Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07889375) titled 'Randomized Trial of the RIGHTEST iFree 2 CGM System for Glycemic Control in Adults With Diabetes Mellitus' on Oct. 16.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Bionime Corporation
Condition:
Diabetes (DM)
Intervention:
Device: Continuous Glucose Monitoring (CGM)
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: May 15, 2026
Target Sample Size: 324
Countries of Recruitment:
Taiwan
To know more, visit https://clinicaltrials.gov/study/NCT07889375
Disc...